Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis

BACKGROUND: Data on the success rate of sitafloxacin treatment in acute complicated urinary tract infection and pyelonephritis are limited. OBJECTIVES: To determine the success rate of a new oral fluoroquinolone, sitafloxacin, in acute complicated urinary tract infection and pyelonephritis. METHODS: A prospective study of 30 patients who were diagnosed with acute complicated urinary tract infection and pyelonephritis was conducted. Oral sitafloxacin 50 mg twice a day was given for 7 days. All patients were followed up at baseline, day 7, and day 14. RESULTS: The patient sample included 67 % females; the mean ± SD age was 49 ± 13 years. Twenty-one (70 %) patients had acute pyelonephritis and 9 (30 %) had complicated urinary tract infections. Twenty-two patients were positive for uropathogens. The most frequently isolated pathogen was E. coli 11 non-extended spectrum beta-lactamase (ESBL) producing and 5 ESBL-producing strains. Of the 22 isolated uropathogens, 19 (86 %) isolates were sensitive to sitafloxacin. At day 14, 29 of 30 (97 %) were clinically cured and 21 of 22 (95 %) were microbiologically cured. No patients discontinued sitafloxacin due to adverse events. CONCLUSIONS: These results support the use of oral sitafloxacin in complicated urinary tract infections and acute pyelonephritis. However, further larger studies are required to confirm these results.